Barcena J, Zamora-Ceballos M, Blanco E
Subcell Biochem. 2024; 105:785-821.
PMID: 39738963
DOI: 10.1007/978-3-031-65187-8_21.
Shao S, Zhang X, Hou J, Yang S, Han Z, Wu H
NPJ Vaccines. 2024; 9(1):62.
PMID: 38503757
PMC: 10951352.
DOI: 10.1038/s41541-024-00855-7.
Choi Y, Kim D, Jang J, Kim B
Front Immunol. 2023; 14:1155637.
PMID: 37334373
PMC: 10272379.
DOI: 10.3389/fimmu.2023.1155637.
Zhao S, Han X, Lang Y, Xie Y, Yang Z, Zhao Q
Front Microbiol. 2023; 14:1117135.
PMID: 36922967
PMC: 10008873.
DOI: 10.3389/fmicb.2023.1117135.
Sazegari S, Akbarzadeh Niaki M, Afsharifar A, Niazi A, Derakhshandeh A, Moradi Vahdat M
Microb Cell Fact. 2023; 22(1):39.
PMID: 36841778
PMC: 9958315.
DOI: 10.1186/s12934-023-02043-z.
Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system.
Armero-Gimenez J, Wilbers R, Schots A, Williams C, Finnern R
Front Immunol. 2023; 14:1088852.
PMID: 36776898
PMC: 9909599.
DOI: 10.3389/fimmu.2023.1088852.
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.
Jimenez-Cabello L, Utrilla-Trigo S, Barreiro-Pineiro N, Pose-Boirazian T, Martinez-Costas J, Marin-Lopez A
Vaccines (Basel). 2022; 10(7).
PMID: 35891288
PMC: 9319458.
DOI: 10.3390/vaccines10071124.
GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A .
Palmieri E, Kis Z, Ozanne J, Di Benedetto R, Ricchetti B, Massai L
Vaccines (Basel). 2022; 10(7).
PMID: 35891202
PMC: 9324507.
DOI: 10.3390/vaccines10071034.
Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition.
Menzies S, Dawson C, Crittenden E, Edge R, Hall S, Alsolaiss J
Sci Rep. 2022; 12(1):11328.
PMID: 35790745
PMC: 9256628.
DOI: 10.1038/s41598-022-13376-x.
Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.
Zhao Y, Li Z, Voyer J, Li Y, Chen X
ACS Appl Mater Interfaces. 2022; 14(19):21872-21885.
PMID: 35467839
PMC: 9121874.
DOI: 10.1021/acsami.2c01028.
Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.
Shoja Z, Jalilvand S, Latifi T, Roohvand F
Arch Virol. 2022; 167(4):1013-1023.
PMID: 35292854
PMC: 8923333.
DOI: 10.1007/s00705-022-05407-9.
Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.
Hemmati F, Hemmati-Dinarvand M, Karimzade M, Rutkowska D, Eskandari M, Khanizadeh S
Biotechnol Lett. 2021; 44(1):45-57.
PMID: 34837582
PMC: 8626723.
DOI: 10.1007/s10529-021-03211-0.
A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics.
Kumar M, Kumari N, Thakur N, Bhatia S, Saratale G, Ghodake G
Plants (Basel). 2021; 10(6).
PMID: 34203729
PMC: 8232254.
DOI: 10.3390/plants10061213.
Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation.
Zhang B, Yin S, Wang Y, Su Z, Bi J
Eng Life Sci. 2021; 21(6):438-452.
PMID: 34140854
PMC: 8182290.
DOI: 10.1002/elsc.202000104.
Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.
Chen C, Saubi N, Joseph-Munne J
Front Immunol. 2020; 11:573157.
PMID: 33117367
PMC: 7561392.
DOI: 10.3389/fimmu.2020.573157.
Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus.
Mobini S, Chizari M, Mafakher L, Rismani E, Rismani E
Front Immunol. 2020; 11:2074.
PMID: 33042118
PMC: 7521014.
DOI: 10.3389/fimmu.2020.02074.
Improving immunogenicity and safety of flagellin as vaccine carrier by high-density display on virus-like particle surface.
Zhao Y, Li Z, Zhu X, Cao Y, Chen X
Biomaterials. 2020; 249:120030.
PMID: 32315864
PMC: 7218678.
DOI: 10.1016/j.biomaterials.2020.120030.
In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection.
Zawawi A, Forman R, Smith H, Mair I, Jibril M, Albaqshi M
PLoS Pathog. 2020; 16(3):e1008243.
PMID: 32203551
PMC: 7117776.
DOI: 10.1371/journal.ppat.1008243.
A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT receptors.
Wu H, Wang Y, Wang G, Qiu Z, Hu X, Zhang H
Br J Pharmacol. 2019; 177(2):402-419.
PMID: 31625597
PMC: 6989956.
DOI: 10.1111/bph.14875.
An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains.
Sun W, Zheng A, Miller R, Krammer F, Palese P
Vaccines (Basel). 2019; 7(3).
PMID: 31540436
PMC: 6789539.
DOI: 10.3390/vaccines7030117.